Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Subungual malignant melanoma"'
Publikováno v:
Actas Dermo-Sifiliográficas (English Edition). 108:482-485
Publikováno v:
Turk Dermatoloji Dergisi, Vol 12, Iss 1, Pp 65-67 (2018)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Der Hautarzt. 68:64-66
Pigmentary nail changes may have a variety of causes, e. g., chronic inflammation, and occur more often in patients of African descent compared to Caucasians. Subungual malignant melanoma is the most important differential diagnosis and must be ruled
Publikováno v:
Bangladesh Journal of Medical Science. 12:322-325
A rare case of subungual malignant melanoma in a 43-year-old male, with black dystrophic right thumb nail plate with positive Hutchison sign is presented. Early detection in malignant melanoma is vital for improved treatment outcomes and prognosis. S
Autor:
Sakuhei Fujiwara, Mizuki Goto, Yukako Ito, Aiko Kato, Haruna Matsuda, Mayuko Goto, Yutaka Hatano, Yoshitaka Kai, Shigeo Yokoyama, Kazumoto Katagiri, Fumiaki Shimizu
Publikováno v:
Nishi Nihon Hifuka. 72:101-105
Publikováno v:
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 187(12)
A 53-year-old man presented with a painless black discolouration affecting the complete nail of his right thumb ([Figure 1][1]). The discolouration had begun 15 years previously as a thin black line stretching from the lunula to the free edge of the
Autor:
Daisuke Tsuruta, Keisuke Goto, Riei Kamo, Junko Sowa-Osako, Shigeto Yanagihara, Nao Kusutani, Masahiko Ohsawa
Publikováno v:
The Journal of Dermatology. 44:e73-e74
Autor:
Toshihiko Hoashi, Noriko Shirakawa, Hidehisa Saeki, Yoko Matano, Shin-ichi Ansai, Yoko Funasaka
Publikováno v:
The Journal of Dermatology. 43:1361-1362
Publikováno v:
International Journal of Dermatology. 46:13-15
A 47-year-old male developed both longitudinal melanonychia and periungual hyperpigmentation 6 months after initiation of hydroxycarbamide (synonym: hydroxyurea) therapy for chronic myeloproliferative disease. Based on the clinical symptoms observed